Tumor Cell Proliferation in Early Gastric Cancer: Biological and Clinical Behavior

Paolo Dionigi, Alberta Ferrari, Vassili Jemos, Orietta Luinetti, Luciano Vai, Michela Guizzetti, Cinzia Ferrari, Kostantinos Jemos, Marco Spada, Giuliano Mazzini

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aims: Recently, early gastric cancers without lymph node metastasis have successfully been removed through a simple endoscopic resection. Tumor cell proliferation may be related to the malignant potential of early gastric cancer. The purpose of this study is to perspectively investigate the relationship between the incorporation rate of bromodeoxyuridine (BrdU) into the DNA of dividing cells, and the main biological and clinical early gastric cancer characteristics. Methodology: Multiple tumor specimens were taken from 27 early gastric cancers and analyzed through anti-BrdU monoclonal antibody. Tumor BrdU labeling index (LI=% positive cells over 2,000 tumor cells) was determined. Early gastric cancers were evaluated in tumor size, mucosal and submucosal involvement, histologic type and grading, lymphatic and venous invasion, and nodal metastasis. Results: BrdU LI was significantly higher in patients with submucosal neoplastic invasion, Pen A Kodama type, tumor vessel invasion and lymph node involvement. Early gastric cancer patients with over 22% BrdU LI showed a significantly higher incidence of submucosal invasion, lymphatic-venous involvement and a reduced survival when compared to patients with medium (12-22%) or low BrdU LI (

Original languageEnglish
Pages (from-to)264-268
Number of pages5
JournalHepato-Gastroenterology
Volume51
Issue number55
Publication statusPublished - Jan 2004

Fingerprint

Bromodeoxyuridine
Stomach Neoplasms
Cell Proliferation
Neoplasms
Lymph Nodes
Neoplasm Metastasis
Monoclonal Antibodies
Survival
DNA
Incidence

Keywords

  • Bromodeoxyuridine
  • Cellular proliferation
  • Early gastric cancer
  • Tumor growth

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Tumor Cell Proliferation in Early Gastric Cancer : Biological and Clinical Behavior. / Dionigi, Paolo; Ferrari, Alberta; Jemos, Vassili; Luinetti, Orietta; Vai, Luciano; Guizzetti, Michela; Ferrari, Cinzia; Jemos, Kostantinos; Spada, Marco; Mazzini, Giuliano.

In: Hepato-Gastroenterology, Vol. 51, No. 55, 01.2004, p. 264-268.

Research output: Contribution to journalArticle

Dionigi, P, Ferrari, A, Jemos, V, Luinetti, O, Vai, L, Guizzetti, M, Ferrari, C, Jemos, K, Spada, M & Mazzini, G 2004, 'Tumor Cell Proliferation in Early Gastric Cancer: Biological and Clinical Behavior', Hepato-Gastroenterology, vol. 51, no. 55, pp. 264-268.
Dionigi, Paolo ; Ferrari, Alberta ; Jemos, Vassili ; Luinetti, Orietta ; Vai, Luciano ; Guizzetti, Michela ; Ferrari, Cinzia ; Jemos, Kostantinos ; Spada, Marco ; Mazzini, Giuliano. / Tumor Cell Proliferation in Early Gastric Cancer : Biological and Clinical Behavior. In: Hepato-Gastroenterology. 2004 ; Vol. 51, No. 55. pp. 264-268.
@article{6f1d4ab7b03b43778d18abaa8d651021,
title = "Tumor Cell Proliferation in Early Gastric Cancer: Biological and Clinical Behavior",
abstract = "Background/Aims: Recently, early gastric cancers without lymph node metastasis have successfully been removed through a simple endoscopic resection. Tumor cell proliferation may be related to the malignant potential of early gastric cancer. The purpose of this study is to perspectively investigate the relationship between the incorporation rate of bromodeoxyuridine (BrdU) into the DNA of dividing cells, and the main biological and clinical early gastric cancer characteristics. Methodology: Multiple tumor specimens were taken from 27 early gastric cancers and analyzed through anti-BrdU monoclonal antibody. Tumor BrdU labeling index (LI={\%} positive cells over 2,000 tumor cells) was determined. Early gastric cancers were evaluated in tumor size, mucosal and submucosal involvement, histologic type and grading, lymphatic and venous invasion, and nodal metastasis. Results: BrdU LI was significantly higher in patients with submucosal neoplastic invasion, Pen A Kodama type, tumor vessel invasion and lymph node involvement. Early gastric cancer patients with over 22{\%} BrdU LI showed a significantly higher incidence of submucosal invasion, lymphatic-venous involvement and a reduced survival when compared to patients with medium (12-22{\%}) or low BrdU LI (",
keywords = "Bromodeoxyuridine, Cellular proliferation, Early gastric cancer, Tumor growth",
author = "Paolo Dionigi and Alberta Ferrari and Vassili Jemos and Orietta Luinetti and Luciano Vai and Michela Guizzetti and Cinzia Ferrari and Kostantinos Jemos and Marco Spada and Giuliano Mazzini",
year = "2004",
month = "1",
language = "English",
volume = "51",
pages = "264--268",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "55",

}

TY - JOUR

T1 - Tumor Cell Proliferation in Early Gastric Cancer

T2 - Biological and Clinical Behavior

AU - Dionigi, Paolo

AU - Ferrari, Alberta

AU - Jemos, Vassili

AU - Luinetti, Orietta

AU - Vai, Luciano

AU - Guizzetti, Michela

AU - Ferrari, Cinzia

AU - Jemos, Kostantinos

AU - Spada, Marco

AU - Mazzini, Giuliano

PY - 2004/1

Y1 - 2004/1

N2 - Background/Aims: Recently, early gastric cancers without lymph node metastasis have successfully been removed through a simple endoscopic resection. Tumor cell proliferation may be related to the malignant potential of early gastric cancer. The purpose of this study is to perspectively investigate the relationship between the incorporation rate of bromodeoxyuridine (BrdU) into the DNA of dividing cells, and the main biological and clinical early gastric cancer characteristics. Methodology: Multiple tumor specimens were taken from 27 early gastric cancers and analyzed through anti-BrdU monoclonal antibody. Tumor BrdU labeling index (LI=% positive cells over 2,000 tumor cells) was determined. Early gastric cancers were evaluated in tumor size, mucosal and submucosal involvement, histologic type and grading, lymphatic and venous invasion, and nodal metastasis. Results: BrdU LI was significantly higher in patients with submucosal neoplastic invasion, Pen A Kodama type, tumor vessel invasion and lymph node involvement. Early gastric cancer patients with over 22% BrdU LI showed a significantly higher incidence of submucosal invasion, lymphatic-venous involvement and a reduced survival when compared to patients with medium (12-22%) or low BrdU LI (

AB - Background/Aims: Recently, early gastric cancers without lymph node metastasis have successfully been removed through a simple endoscopic resection. Tumor cell proliferation may be related to the malignant potential of early gastric cancer. The purpose of this study is to perspectively investigate the relationship between the incorporation rate of bromodeoxyuridine (BrdU) into the DNA of dividing cells, and the main biological and clinical early gastric cancer characteristics. Methodology: Multiple tumor specimens were taken from 27 early gastric cancers and analyzed through anti-BrdU monoclonal antibody. Tumor BrdU labeling index (LI=% positive cells over 2,000 tumor cells) was determined. Early gastric cancers were evaluated in tumor size, mucosal and submucosal involvement, histologic type and grading, lymphatic and venous invasion, and nodal metastasis. Results: BrdU LI was significantly higher in patients with submucosal neoplastic invasion, Pen A Kodama type, tumor vessel invasion and lymph node involvement. Early gastric cancer patients with over 22% BrdU LI showed a significantly higher incidence of submucosal invasion, lymphatic-venous involvement and a reduced survival when compared to patients with medium (12-22%) or low BrdU LI (

KW - Bromodeoxyuridine

KW - Cellular proliferation

KW - Early gastric cancer

KW - Tumor growth

UR - http://www.scopus.com/inward/record.url?scp=10744229737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744229737&partnerID=8YFLogxK

M3 - Article

C2 - 15011882

AN - SCOPUS:10744229737

VL - 51

SP - 264

EP - 268

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 55

ER -